SCHEMBL4692403

SCHEMBL4692403

CN(c1c2c(c(O)c3ncccc13)C(=O)N(Cc1ccc(F)c(F)c1)C2)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 7/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.36
SLC2A1 P11166 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
PDPK1 O15530 1/20 0.34
GLO1 Q04760 1/20 0.33
KDM4E B2RXH2 3/20 0.33
HSP90AA1 P07900 3/20 0.33
RAB9A P51151 3/20 0.33
NPSR1 Q6W5P4 3/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TP53 P04637 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693783 0.93 COMT (0.40) COMTSLC2A1KDM4EHSP90AA1RAB9A
SCHEMBL12378203 0.91 RPS6KB1 (0.38) COMTPTGDR2SLC2A1
SCHEMBL4652222 0.91 KDM4E (0.39) COMTPTGDR2KDM4EHSP90AA1RAB9A
SCHEMBL29390607 0.91 KDM4E (0.39) COMTPTGDR2KDM4EHSP90AA1RAB9A
SCHEMBL5650719 0.90 MAPT (0.38) COMTSLC2A1KDM4ERAB9ANPSR1
SCHEMBL4689848 0.89 COMT (0.38) COMTSLC2A1KDM4EHSP90AA1RAB9A
SCHEMBL12378216 0.89 COMT (0.35) COMTSLC2A1KDM4EHSP90AA1RAB9A
SCHEMBL4750446 0.88 TP53 (0.39) COMTPTGDR2SLC2A1KDM4ERAB9A
SCHEMBL4693347 0.88 COMT (0.38) COMTPTGDR2KDM4EHSP90AA1RAB9A
SCHEMBL5645481 0.88 COMT (0.36) COMTSLC2A1KDM4EHSP90AA1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888581-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2008-02-20 EP disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
WO-2006125048-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072831-A1 Integrase inhibitor compounds TYMP, CDKN1A, PAICS COMT 645/4885PTGDR2 3990/4885SLC2A1 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.